Diagnostics firm Quotient Limited and autoimmune disease testing firm Theradiag are collaborating to advance autoimmune disease testing.
Under the terms of their agreement, Theradiag will supply autoimmune reagents and multiconstituent quality controls for the development of autoimmune microarrays that will be used on the Quotient MosaiQ platform.
The collaboration will begin by focusing on testing for connective tissue diseases, based on screening for antinuclear antibodies and tiered testing for extractable nuclear antigen antibodies.
